Mark Mirochnick
Overview
Explore the profile of Mark Mirochnick including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
112
Citations
1812
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Powis K, Pinilla M, McMorrow F, Stek A, Brooks K, Shapiro D, et al.
J Acquir Immune Defic Syndr
. 2025 Jan;
98(3):300-307.
PMID: 39813286
Background: Limited data exist on bictegravir pharmacokinetics in pregnancy among persons with HIV (PWH) and infant washout. Setting: Nonrandomized, open-label, multicenter phase-IV prospective study of bictegravir pharmacokinetics and safety in...
2.
Bekker A, Capparelli E, Mirochnick M, Clarke D, Cotton M, Shapiro R, et al.
J Antimicrob Chemother
. 2024 Aug;
79(10):2570-2574.
PMID: 39092932
Objectives: To develop a pragmatic twice daily lamivudine dosing strategy for preterm infants from 24 to 37 completed weeks of gestation. Methods: Data were combined from eight pharmacokinetic studies in...
3.
Brooks K, Baltrusaitis K, Clarke D, Nachman S, Jao J, Purswani M, et al.
J Infect Dis
. 2024 Jun;
230(4):878-888.
PMID: 38839047
Background: Pregnant people with coronavirus disease 2019 (COVID-19) experience higher risk for severe disease and adverse pregnancy outcomes, but no pharmacokinetic (PK) data exist to support dosing of COVID-19 therapeutics...
4.
Bekker A, Yang J, Wang J, Cotton M, Cababasay M, Wiesner L, et al.
Pediatr Infect Dis J
. 2024 Jan;
43(4):355-360.
PMID: 38190642
Background: Study of liquid lopinavir/ritonavir (LPV/r) in young infants has been limited by concerns for its safety in neonates. Methods: International Maternal Pediatric Adolescent AIDS Clinical Trials Network P1106 was...
5.
Persaud D, Bryson Y, Nelson B, Tierney C, Cotton M, Coletti A, et al.
Lancet HIV
. 2023 Dec;
11(1):e20-e30.
PMID: 38061376
Background: Infants born with HIV-1 require lifelong antiretroviral therapy (ART). We aimed to assess whether very early ART in neonates might restrict HIV-1 reservoirs, an important step towards ART-free remission....
6.
Momper J, Nikanjam M, Best B, Mirochnick M, Capparelli E, Cressey T
J Acquir Immune Defic Syndr
. 2023 Oct;
94(4):332-336.
PMID: 37884053
Background: Clinical interpretation of the reduced dolutegravir (DTG) plasma concentrations reported during pregnancy is complicated by its high plasma protein binding. Plasma proteins significantly decrease during pregnancy, and understanding changes...
7.
Van Schalkwyk M, Bekker A, Decloedt E, Wang J, Theron G, Cotton M, et al.
Antimicrob Agents Chemother
. 2023 Oct;
67(11):e0073723.
PMID: 37882552
Physiological changes during pregnancy may alter the pharmacokinetics (PK) of antituberculosis drugs. The International Maternal Pediatric Adolescent AIDS Clinical Trials Network P1026s was a multicenter, phase IV, observational, prospective PK...
8.
Brooks K, Scarsi K, Mirochnick M
Obstet Gynecol Clin North Am
. 2023 Feb;
50(1):205-218.
PMID: 36822704
Safe and effective antiretroviral medications are needed during pregnancy to reduce maternal morbidity and mortality associated with untreated human immunodeficiency virus (HIV) infection and to prevent viral transmission to the...
9.
Eke A, Mirochnick M, Lockman S
N Engl J Med
. 2023 Jan;
388(4):344-356.
PMID: 36720135
No abstract available.
10.
Liu X, Dallmann A, Brooks K, Best B, Clarke D, Mirochnick M, et al.
CPT Pharmacometrics Syst Pharmacol
. 2022 Dec;
12(2):148-153.
PMID: 36479969
Pregnant individuals are at high risk for severe illness from COVID-19, and there is an urgent need to identify safe and effective therapeutics for this population. Remdesivir (RDV) is a...